Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLL

CLL: Long-term updates on ibrutinib and idelalisibПодробнее

Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLLПодробнее

Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLLПодробнее

Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimenПодробнее

Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLLПодробнее

The treatment of relapsed/refractory chronic lymphocytic leukemiaПодробнее

OS after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLLПодробнее

CLL: Idelalisib based regimensПодробнее

PI3K/Anti-CD20 Therapy for Relapsed/Refractory CLLПодробнее

Updated analysis of Phase III trial of idelalisib combined with bendamustine and rituximab in CLLПодробнее

Dr. O'Brien Discusses Ibrutinib and Idelalisib in CLLПодробнее

Idelalisib + bendamustine/rituximab (BR) bests BR alone in patients with relapsed/refractory CLLПодробнее

Dr. Jeffrey Jones on Efficacy of Idelalisib/Ofatumumab Combination in CLLПодробнее

Side-effect of idelalisib and its use in chronic lymphocytic leukemiaПодробнее

Understanding the Trial With Idelalisib and RituximabПодробнее

Acalabrutinib VS. Rituximab Combined with Idelalisib or Bendamustine for CLL - ASCO 2022Подробнее

Trial results of idelalisib with bendamustine and rituximab in CLLПодробнее

Idelalisib for Previously Treated CLLПодробнее

Dr. Yazbeck on Idelalisib Plus BR in Relapsed/Refractory CLLПодробнее